XML 18 R54.htm IDEA: XBRL DOCUMENT v3.3.0.814
Segment and Geographical Data (Tables)
 12 Months Ended
Sep. 25, 2015
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment is as follows:

Fiscal Year

2015
 
2014
 
2013
Net sales:
 
 
 
 
 
Specialty Brands
1,622.8

 
413.5

 
206.4

Specialty Generics
1,251.6

 
1,199.4

 
1,011.2

Nuclear Imaging
423.8

 
431.7

 
437.6

Net sales of operating segments (1)
3,298.2

 
2,044.6

 
1,655.2

Other (2)
48.7

 
37.4

 
57.1

Net sales
3,346.9

 
2,082.0

 
1,712.3

Operating income:
 
 
 
 
 
Specialty Brands
651.3

 
(50.6
)
 
(36.2
)
Specialty Generics
622.0

 
617.4

 
347.9

Nuclear Imaging
66.4

 
(16.7
)
 
24.5

Segment operating income
1,339.7

 
550.1

 
336.2

Unallocated amounts:
 
 
 
 
 
Corporate and allocated expenses (3)          
(286.9
)
 
(228.1
)
 
(134.3
)
Intangible asset amortization
(550.3
)
 
(154.8
)
 
(27.9
)
Restructuring and related charges, net (4)
(40.7
)
 
(81.9
)
 
(26.3
)
Non-restructuring impairments
—

 
(151.6
)
 
—

Separation costs
—

 
(9.6
)
 
(74.2
)
Operating income (loss)
461.8

 
(75.9
)
 
73.5

 
 
 
 
 
 
Depreciation and amortization (5):
 
 
 
 
 
Specialty Brands
559.8

 
152.9

 
24.9

Specialty Generics
81.9

 
77.8

 
72.7

Nuclear Imaging
12.4

 
18.8

 
18.5

Depreciation and amortization
654.1

 
249.5

 
116.1

(1)
Amounts represent sales to external customers. There were no intersegment sales.
(2)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
(3)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(4)
Includes restructuring-related accelerated depreciation.
(5)
Depreciation for certain shared facilities is allocated based on occupancy percentage.
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's segments are as follows:

 
Fiscal Year
 
2015
 
2014
 
2013
Acthar
$
1,037.3

 
$
122.9

 
$
—

Ofirmev
263.0

 
124.4

 
—

Inomax
185.2

 
—

 
—

Exalgo
39.4

 
76.1

 
126.1

Other
97.9

 
90.1

 
80.3

Specialty Brands
1,622.8

 
413.5

 
206.4

 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
167.2

 
99.4

 
140.0

Oxycodone (API) and oxycodone-containing tablets
154.6

 
155.2

 
139.0

Methylphenidate ER
136.5

 
209.6

 
148.3

Other controlled substances
572.2

 
584.5

 
443.3

Other
221.1

 
150.7

 
140.6

Specialty Generics
1,251.6

 
1,199.4

 
1,011.2

 
 
 
 
 
 
Nuclear Imaging
423.8

 
431.7

 
437.6

 
 
 
 
 
 
Other (1)
48.7

 
37.4

 
57.1

Net sales
$
3,346.9

 
$
2,082.0

 
$
1,712.3


(1)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
Schedule of Net Sales and Long-Lived Assets by Geographical Area
Selected information by geographic area excluding assets held for sale is as follows:
 
Fiscal Year
 
2015
 
2014
 
2013
Net sales (1):
 
 
 
 
 
U.S.
$
2,973.2

 
$
1,780.9

 
$
1,421.6

Europe, Middle East and Africa
236.2

 
250.3

 
250.1

Other
137.5

 
50.8

 
40.6

 
$
3,346.9

 
$
2,082.0

 
$
1,712.3

Long-lived assets (2):
 
 
 
 
 
U.S.
$
905.2

 
$
829.1

 
 
Europe, Middle East and Africa (3)
45.0

 
33.9

 
 
Other
44.5

 
41.0

 
 
 
$
994.7

 
$
904.0

 
 
(1)
Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.
(2)
Long-lived assets are primarily composed of property, plant and equipment.
(3)
Includes long-lived assets located in Ireland of $10.7 million, and $0.4 million at the end of fiscal 2015 and 2014, respectively.